Northern Trust Corp Cyclo Therapeutics, Inc. Transaction History
Northern Trust Corp
- $586 Billion
- Q2 2024
A detailed history of Northern Trust Corp transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 21,722 shares of CYTH stock, worth $16,291. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,722
Previous 21,741
0.09%
Holding current value
$16,291
Previous $30,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CYTH
# of Institutions
23Shares Held
2.24MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA817KShares$612,9520.39% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$360,53172.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA447KShares$334,9290.0% of portfolio
-
Geode Capital Management, LLC Boston, MA175KShares$131,5630.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$82,517100.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $6.33M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...